News

Lucjan Wyrwicz, MD, Maria Sklodowska Curie National Cancer Research Institute

Videos

Continued Benefit From Pembrolizumab Plus Chemotherapy in Later-Line Therapy for Patients With Advanced, HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma

07/12/2023

L. Wyrwicz ;

At the 2023 World Congress on Gastrointestinal Cancers, Lucjan Wyrwicz discusses the extended benefit of pembrolizumab plus chemotherapy when evaluating outcomes on next-line therapy for advanced HER2-negative, gastric/gastroesophageal...

At the 2023 World Congress on...

07/12/2023

Oncology

Conference Coverage

Nivolumab Plus Chemotherapy Decreases Risk of Deterioration in Health-Related Quality of Life for Patients With Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma

06/30/2023

Allison Casey ;

According to 3-year data, patients with GC/GEJC/EAS treated with nivolumab plus chemotherapy in the CheckMate 649 trial generally maintained health-related quality of life compared to chemotherapy alone.

According to 3-year data,...

06/30/2023

Oncology

Conference Coverage

No Benefit From Adjuvant Nivolumab-Ipilimumab for Patients With Gastroesophageal Adenocarcinoma At High Risk of Relapse

06/29/2023

Allison Casey ;

According to a phase 2 study, adjuvant nivolumab-ipilimumab did not improve disease-free survival for patients with gastroesophageal adenocarcinoma at high-risk for relapse following resection, compared with chemotherapy.

According to a phase 2 study,...

06/29/2023

Oncology

Conference Coverage

Potential Benefit to Response Rates From Trastuzumab Added to Perioperative Chemotherapy for Patients with HER2-Positive Gastric/Gastroesophageal Junction Cancers

06/29/2023

Allison Casey ;

A phase 2 trial evaluated the addition of trastuzumab, with or without pertuzumab to perioperative chemotherapy for patients with HER2-positive gastric or gastroesophageal cancer.

A phase 2 trial evaluated the...

06/29/2023

Oncology

Conference Coverage

Sugemalimab Added to Chemotherapy Improves Survival, Response Rates for Patients With Advanced Esophageal Squamous Cell Carcinoma

06/29/2023

Allison Casey ;

According to results from a phase 3 study, sugemalimab added to chemotherapy improved progression-free survival, overall survival, and objective response rate, for patients with advanced esophageal squamous cell carcinoma.

According to results from a...

06/29/2023

Oncology

Conference Coverage

Addition of Pembrolizumab to Chemotherapy Continues Benefit in Subsequent Therapies for Patients with HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma

06/29/2023

Allison Casey ;

According to data from an ad hoc analysis of the KEYNOTE-859 study, pembrolizumab added to first-line chemotherapy continues to benefit patients with locally advanced or metastatic HER2-negative gastric/gastroesophageal cancer in outcomes of...

According to data from an ad hoc...

06/29/2023

Oncology

News

Frontline Tislelizumab Plus Chemotherapy for Patients With Gastroesophageal Squamous Cell Carcinoma

05/23/2023

In a phase 3 trial, tislelizumab plus chemotherapy improved the overall survival of patients with advanced or metastatic gastroesophageal squamous cell carcinoma when compared with placebo plus chemotherapy.

In a phase 3 trial, tislelizumab...

05/23/2023

Oncology

Anup Kasi, MD, University of Kansas Cancer Center

Videos

Adjuvant Immunotherapy for Upper GI Tract Cancers

04/20/2023

Anup Kasi, MD, discusses the debate on neoadjuvant vs adjuvant immunotherapy for patients with locally advanced HER2-positive upper gastrointestinal tract cancers, held at the 2023 Great Debates and Updates in GI Malignancies in Chicago.

Anup Kasi, MD, discusses the...

04/20/2023

Oncology

Arvind Dasari, MD, MD Anderson Cancer Center

Videos

New and Upcoming Options for Neuroendocrine Tumors

04/13/2023

Arvind Dasari, MD, reviews the new and upcoming treatment options for patients with neuroendocrine tumors at the 2023 Great Debates and Updates in GI Malignancies in Chicago.

Arvind Dasari, MD, reviews the...

04/13/2023

Oncology

Videos

The Role of Genetics in the Management of Patients with Gastrointestinal Cancer

04/01/2023

At the 2023 Great Debates & Updates in Gastrointestinal Malignancies in Chicago, regional co-chair Sonia Kupfer, MD, discussed the significant part that genetics play when treating patients with gastrointestinal cancers.

At the 2023 Great Debates &...

04/01/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology